Clinical Outcome After Implantation Of Clareon Panoptix® Presbyopia Correcting Iol

To evaluate outcomes on visual acuity at different distances, range of vision, patient satisfaction, spectacle independence, visual quality and refractive outcomes in cataract and refractive lens exchange patients implanted with the trifocal Clareon PanOptix®/ Toric IOL.

Department of Ophthalmology, Goethe University, Frankfurt, Germany

Interim analysis of a prospective, single-site, clinical trial in our hospital including patients after bilateral implantation of the Clareon PanOptix IOL. After 3-, 6- and 12-months follow-up, binocular uncorrected and corrected visual acuities at distance (UCDVA, BCDVA), intermediate (UCIVA, DCIVA) and near (UCNVA, DCNVA) will be measured. Spectacle independence, defocus curve ranging from -5.0 D to +2.0 D in 0.5D steps, patient satisfaction and visual disturbances will be also evaluated. In this ongoing trial, we have so far recruited 21 subjects implanted with the trifocal IOL.

Up to now we have enrolled 21 patients with an average age of 63.9 ± 7.03 years in the clinical trial. Three months postoperative (8 patients until now) monocular UDVA, UIVA in 60cm and 80cm was >0.1logMAR and UNVA in 40cm and 30cm was >0.2logMAR. Binocular UDVA, UIVA in 60cm and 80cm and UNVA in 40cm and 30cm was >0.1logMAR. Defocus curve shows two peaks at 0D and 2D. All analyzed patients do not need spectacles. 50% of the included patients reported halos at night. Contrast sensitivity was 1.63 ± 0.47logCS under photopic conditions, 1.03 ± 0.32 logCS under mesopic conditions and 0.86 ± 0.17 logCS under mesopic with glare conditions. At the congress 3 months postoperative data of 27 patients will be presented.

Visual performance of the PanOptix IOL showed good VA at all distances, high patient satisfaction and spectacle independence with good contrast sensitivity 3 months postoperatively.